France to start using Pfizer's COVID-19 drug, first in EU

France says it will start administering Pfizer’s coronavirus antiviral drug this week, the first pill for treating COVID-19 approved in the 27-nation EU

Via AP news wire
Wednesday 02 February 2022 16:39
Virus Outbreak France
Virus Outbreak France

France says it will start administering Pfizer’s coronavirus antiviral drug this week, the first pill for treating COVID-19 approved in the 27-nation EU.

The country is still reporting among the world's highest per-capita daily infections, but virus-related critical care hospitalizations are easing, and the French government on Wednesday started lifting restrictions related to the surge in omicron cases.

Masks are now no longer required outdoors in France, large crowds are again allowed in concerts and sports venues and a government order to work from home part-time has been lifted.

Meanwhile, France has received its first 10,000 doses of the Pfizer drug Paxlovid and they will be available in pharmacies starting Friday, the Health Ministry said Wednesday. It says it's the first European Union country to start providing the treatment since it won regulatory approval last week.

It will be given to adults with symptoms who don’t require oxygen and who are at higher risk of severe disease, according to European Medicines Agency guidelines. Supplies of the drug remain limited worldwide.

The EMA last week recommended that Paxlovid be authorized for use, saying it could help people infected with COVID-19 avoid more serious disease and being hospitalized. The drug was cleared by regulators in the U.S. and Britain in December.

An antiviral pill from Merck also is expected to soon be authorized. Both drugs are expected to be effective against omicron because they do not target the spike protein where most of the variant’s worrisome mutations reside.

___

Follow all AP stories on the pandemic at https://apnews.com/hub/coronavirus-pandemic.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in